Meckler Jeffrey A 4

4 · Indaptus Therapeutics, Inc. · Filed Apr 11, 2025

Form 4

Period: 2025-04-10

DirectorCo-Chief Executive Officer

Transactions

Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.04/sh−4,750$176→ 0 total
Exercise: $536.00From: 2017-12-11Exp: 2027-12-11→ Common Stock (4,750 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.04/sh−813$30→ 0 total
Exercise: $425.60From: 2017-05-01Exp: 2027-05-01→ Common Stock (813 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.04/sh−1,563$58→ 0 total
Exercise: $611.20From: 2019-04-04Exp: 2026-04-04→ Common Stock (1,563 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.04/sh−1,250$46→ 0 total
Exercise: $355.20From: 2018-06-28Exp: 2025-06-28→ Common Stock (1,250 underlying)
Disposition to Issuer
sStock Option (right to buy)
2025-04-10$0.04/sh−1,500$56→ 0 total
Exercise: $425.60From: 2017-04-10Exp: 2027-04-10→ Common Stock (1,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-04-10$0.04/sh−3,750$139→ 0 total
Exercise: $24.60From: 2020-07-15Exp: 2027-07-15→ Common Stock (3,750 underlying)

Footnotes (1)

[F1]The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation.

Documents

1 file